American Cryostem Corporation 2017 Year End Update

January 16, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / January 16, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding the Company's Year ending September 30, 2017; Total Revenue increased to $1,865,364 in Fiscal...

Read more

American CryoStem Statement on the Receipt of a Warning Letter from FDA

January 8, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / January 8, 2018 / American CryoStem Corporation (PINK SHEETS: CRYO)) today issued a statement acknowledging that it has received a warning letter issued by the U.S. Food & Drug Administration (FDA) dated January 3, 2018 relating to its adipose derived stem cell product and its production facilities. This action follows the earlier inspections of the Company's New Jersey facility by the agency between July 17 and...

Read more

Molecular Partners Reports Promising Initial Safety and Efficacy Data From its Ongoing phase 2 Study of MP0250 in Multiple Myeloma

January 8, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 8, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM). Eight patients have been treated in the first cohort of 8 mg/kg MP0250 and were included in the safety analysis set. No...

Read more

Molecular Partners to Present at The 36th Annual J.P. Morgan Healthcare Conference

January 4, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 4, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, 10 January, 2018 at 8:30 AM Pacific Standard Time (11:30 AM Eastern Time; 5:30 PM CET). The presentation, followed by a Q&A session,...

Read more

LBTD Explains COIN Rig Solutions, Obtains First Servers for Intelligent Mining and Global Strategy of Monetization

December 27, 2017 2:00 PM

KOWLOON, HONG KONG / ACCESSWIRE / December 27, 2017 / Mr. William Ko, President, president of LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. (OTC PINK: LBTD) is excited to announce the company's intelligent mining strategy for digital currency. It has obtained its first shipment of servers for inspection and testing. Follow us on our twitter feed for updates @lbtd_coin_rig The current combined market cap of all cryptocurrencies is valued at...

Read more

LBTD Agrees to Purchase COIN Solutions to Enter Cryptocurrency with Cutting Edge Algorithm and Artificial Intelligence Software

December 22, 2017 3:30 PM

KOWLOON, HONG KONG / ACCESSWIRE / December 22, 2017 / Mr. William Ko, President of LBTD, is excited to announce that: LOTUS BIO- TECHNOLOGY DEVELOPMENT CORP. (OTC PINK: LBTD) has entered into a significant agreement with COIN RIG SOLUTION (Coin), an Ontario, Canada Cryptocurrency Algorithm and Encryption Company. The agreement allows LBTD to lead the Cryptocurrency market with its own algorithm optimizing Artificial Intelligence (AI) that allows...

Read more

Calmare Therapeutics Cautions Shareholders

December 20, 2017 10:37 AM

FAIRFIELD, CT / ACCESSWIRE / December 20, 2017 / Calmare Therapeutics Incorporated (OTC PINK: CTTC) ("CTI"), the pain mitigation company ("Calmare"), today confirmed that a definitive consent solicitation statement has been filed with the U.S. Securities and Exchange Commission ("SEC") by a minority complaining group of stockholders (the "Minority Complaining Group"). In their statement, the Minority Complaining Group have stated their intent...

Read more

Pressure BioSciences Enters Biopharmaceutical Quality Control Market with Significant Software Upgrade for Its Flagship Barocycler 2320EXTREME

December 20, 2017 9:35 AM

Greatly Enhanced Software Provides Necessary Features for GMP Compliance and Ensures Highly Reproducible Sample Preparation for Quality Control of Biotherapeutics SOUTH EASTON, MA / ACCESSWIRE / December 20, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based products and services for the worldwide life sciences industry, today announced...

Read more

AYOXXA To Present @ Biotech Showcase 2018

December 20, 2017 7:45 AM

COLOGNE, GERMANY / ACCESSWIRE / December 20, 2017 / AYOXXA Biosystems GmbH, an international biotechnology company focused on the development of innovative multiplex protein analysis platform enabling translational science in basic and clinical research, will present at the upcoming Biotech Showcase 2018 on January 8-10, 2018 at the Hilton San Francisco Union Square, San Francisco, CA, U.S. This conference features presentations from up and...

Read more

Pressure BioSciences, Inc. to Host Business Update on Wednesday, December 20th at 4:30 pm EST

December 18, 2017 9:29 AM

Discussions to Include Purchase of All BaroFold's Assets, Issuances of Patents on the Company's Ultra Shear Technology (UST) Platform, Enhancements to the Company's Core Business Segment (Research Products & Services), and a Brief Outlook for FY2018 SOUTH EASTON, MA / ACCESSWIRE / December 18, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to provide an...

Read more

MorphoSys to Present at Upcoming Investor Conferences

December 14, 2017 10:20 AM

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / December 14, 2017 / MorphoSys AG (FRA: MOR; Prime Standard Segment, TecDAX; XETRA: MOR; OTC PINK: MPSYY) will present at the following conferences: J.P. Morgan Annual Healthcare Conference Date: January 10, 2018, 12:00 pm PST (09:00 pm CET, 8:00 pm GMT) Venue: San Francisco, CA, USA Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG Jens Holstein, Chief Financial...

Read more

Pressure BioSciences Announces Acquisition of All Assets of BaroFold, Inc.

December 13, 2017 9:15 AM

Acquisition to Combine BaroFold's Patented High-Pressure Protein Refolding Technology with PBI's Leadership in High-Pressure Instrumentation and Worldwide Market AccessCompany Plans Immediate Entry into the Biologics Contract Research Services Sector SOUTH EASTON, MA / ACCESSWIRE / December 13, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling,...

Read more

MorphoSys AG: Corporate Calendar 2018

December 11, 2017 10:20 AM

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / December 11, 2017 / MorphoSys AG (XETRA: MOR; FRA: MOR; OTC PINK: MPSYY): Corporate Calendar 2018. Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2018 as follows: March 13, 2018: Year-End 2017 Results May 3, 2018: Publication of First Quarter Interim Statement 2018 August 2, 2018: Publication of Half-Year Report 2018 November 6, 2018: Publication of Third...

Read more

XCELL BIOLOGIX(TM) Signs Exclusive Worldwide Licensing Agreement with the Wake Forest Institute for Regenerative Medicine for Development and Commercialization of Novel Tissue Regeneration Technology for Healing Chronic Wounds and Severe Burns

December 11, 2017 9:00 AM

KENNESAW, GA / ACCESSWIRE / December 11, 2017 / XCELL BIOLOGIX™, a private company focused on commercializing innovative regenerative medicine technologies, today announced that it has entered into an exclusive worldwide license agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), part of Wake Forest School of Medicine, for development and commercialization of its novel amnion derived product candidates that...

Read more

MorphoSys Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference

December 11, 2017 8:30 AM

- Preliminary median progression-free survival of 11.3 months - Objective response rate (ORR) of 52%, complete remission rate (CR) of 32% - No unexpected toxicities observed; no infusion-related reactions reported for MOR208 - MOR208 plus lenalidomide recently received FDA Breakthrough Therapy designation for non-transplant eligible patients with R/R DLBCL PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 11, 2017 / MorphoSys AG (FSE: MOR; XETRA:...

Read more

MorphoSys to Host Investor & Analyst Call On December 12, 2017 About Data On MOR208 Presented at the 2017 ASH Annual Meeting

December 5, 2017 9:30 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 5, 2017 / MorphoSys AG (FSE: MOR; XETRA: FOR; Prime Standard Segment, TecDAX) will host an Investor & Analyst conference call and webcast on its investigational proprietary program MOR208 on December 12, 2017 at 5:00 pm CET (4:00 pm GMT, 11:00 am EST) after the 2017 ASH Annual Meeting. In the call, the MorphoSys Management will present and discuss updated clinical data from the ongoing phase 2...

Read more

AYOXXA Launches LUNARIS(TM) Human 11-Plex Ophthalmology Kit

December 5, 2017 3:30 AM

LUNARISTM Human 11-Plex Ophthalmology Kit allows accurate and precise quantitative analysis of retinal angiogenic diseases (RAD)-related biomarker signatures from scarce human vitreous and aqueous humor samples Kit covers a comprehensive selection of angiogenic and inflammatory factors as well as chemokines found to play significant roles in the pathology of retinal angiogenic diseases (RAD) next to vascular endothelial...

Read more

MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada

December 5, 2017 2:00 AM

Janssen's Tremfya(R) now approved in the U.S., Canada and the European Union PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 5, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its licensee Janssen Inc. (Janssen), previously reported Health Canada approval of Tremfya(R) (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic...

Read more

Ad Hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab

November 30, 2017 6:00 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 30, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and I-Mab announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSys's proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in...

Read more

MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab

November 30, 2017 5:45 AM

- MorphoSys to receive a USD 20 million upfront payment and entitled to tiered, double-digit royalties on net sales of MOR202 plus milestone payments of up to USD 100 million from I-Mab - I-Mab receives exclusive development and commercialization rights to MOR202 in China, Taiwan, Hong Kong and Macao - I-Mab Biopharma (a fully owned affiliate of I-Mab) management has extensive experience that is particularly well-suited to developing MOR202...

Read more